1.3 Peak Bone Mass, Calcium Homeostasis & Skeletal Aging
Key Takeaways
Peak bone accrual varies by skeletal region and maturation. Heritability describes variation within a studied population.
PTH promotes calcium conservation and calcitriol production and reduces renal phosphate reabsorption.
FGF23 promotes phosphate excretion and lowers calcitriol. Evaluate the resulting mineral pattern in the setting of kidney function.
Menopause-related acceleration and other age-related changes can overlap, with varying cortical and trabecular effects.
Understand the trajectory of bone accrual
Peak bone mass describes the maximum amount of bone attained at a site or in the whole skeleton. A longitudinal study from Saskatchewan found substantial accrual around the adolescent growth spurt and different trajectories across sites. Interpret peak timing with the skeletal region, measurement, sex and stage of maturation in mind. Height growth, bone mineral accrual and consolidation can follow different timelines. A single birthday is not the age of peak at every site.
Genetic variation contributes to the range of bone traits. Family and twin studies measure how much variation in a study population is associated with genetic differences. Such an estimate does not partition an individual's bone mass into inherited and modifiable percentages. Mechanical loading, nutrition, growth, sex hormones and health also affect accrual. Consider restricted intake, delayed puberty and low energy availability when evaluating a young person, and use the applicable pediatric or premenopausal assessment. In physically active adolescents, menstrual dysfunction in the setting of low energy availability can signal impaired bone accrual. The course depends on the individual and response to treatment.
Adequate calcium and vitamin D support mineralization. As a U.S. dietary reference example, the recommended calcium intake at ages 9–18 is 1,300 mg/day and vitamin D is 600 IU/day. These are intake recommendations, and deficiency treatment is a different decision. The likely effect of a childhood exposure depends on duration, timing and other factors. A greater peak can provide a higher starting point for later life, but it does not establish an individual's future rate of loss or fracture probability.
Follow calcium and phosphate regulation
The calcium-sensing receptor (CaSR) helps parathyroid cells respond to extracellular ionized calcium. When ionized calcium falls, reduced CaSR activation promotes parathyroid hormone (PTH) secretion. Calcium measurement, albumin, kidney function and the clinical setting matter when interpreting a patient result. Use local laboratory intervals.
| Regulator | Main actions to recognize |
|---|---|
| PTH | Promotes renal calcium conservation, reduces renal phosphate reabsorption and stimulates renal activation of vitamin D. Sustained excess can increase skeletal turnover. |
| Calcitriol | Active 1,25-dihydroxyvitamin D increases intestinal absorption of calcium and phosphate. The usual nutritional-status test measures 25-hydroxyvitamin D instead. |
| FGF23 | Produced largely by osteocytes and osteoblasts. In kidney signaling that involves α-Klotho, it reduces phosphate reabsorption and lowers calcitriol through reduced synthesis and increased catabolism. |
| Calcitonin | Secreted by thyroid C cells. It can inhibit osteoclast-mediated resorption. PTH and vitamin D are central to day-to-day calcium regulation. |
Vitamin D undergoes 25-hydroxylation, principally in the liver, and renal CYP27B1 produces circulating calcitriol. Renal FGF23 signaling reduces phosphate transporter abundance and CYP27B1 activity and increases the pathway involving CYP24A1. In CKD, FGF23 can rise before overt hyperphosphatemia or increased PTH. Kidney function, phosphate, calcium and vitamin D influence the observed pattern. Use trends and applicable CKD guidance, since one proposed sequence does not describe every patient.
Exposure pattern matters in bone. Chronic PTH excess can increase resorption and lead to cortical-rich site deficits in primary hyperparathyroidism. The pattern is variable, and biochemical evaluation establishes the diagnosis. Intermittent teriparatide can increase bone formation and later resorption, creating an early difference in their time courses. Its clinical indications are defined by labeling and guideline context.
Recognize overlapping patterns of adult bone loss
Bone loss can begin at different ages in different compartments. A longitudinal QCT study observed trabecular loss beginning in younger adulthood in both women and men, with cortical loss beginning later in the sampled peripheral sites. SWAN found that BMD loss accelerated around the final menstrual period and later slowed, with differences by site and participant. The menopause transition can affect both compartments and does not define a fixed annual rate for any individual.
With advancing age, thinning and loss of trabeculae, cortical thinning or greater cortical porosity can all contribute to reduced strength. Changes in turnover balance, sex steroids, loading, health and renal function vary. Consider fall risk and fracture history with the measured BMD. As an example, an observed decline around menopause is consistent with a population pattern, but clinical interpretation still requires valid serial scans and review for other contributors. Neither age nor menopause assigns a mechanism to a single scan.
Peak accrual cohort · Bone density twin study · NIH ODS calcium · NIH ODS vitamin D · Endocrine Society functional hypothalamic amenorrhea guideline · CaSR cloning experiment · FGF23 experiment · FGF23 and CKD cohort · KDIGO CKD-MBD · Fifth PHPT Workshop · Forteo label · SWAN · Longitudinal QCT cohort
Which distinction describes chronic PTH excess and intermittent teriparatide exposure?
Both cause only osteoclast suppression.
Chronic PTH excess and intermittent teriparatide have identical effects in every skeletal region.
Chronic PTH excess can increase turnover and affect cortical-rich sites. Intermittent teriparatide can raise formation early in treatment.
Intermittent teriparatide prevents any increase in resorption throughout treatment.
Which renal effects are consistent with increased FGF23 signaling in the physiological pathway?
More phosphate reabsorption and higher calcitriol.
More phosphate reabsorption and no change in vitamin D metabolism.
Direct intestinal calcium transport without a renal effect.
Less phosphate reabsorption and lower calcitriol.
A report describes both acceleration around menopause and trabecular loss in some younger adults. Which interpretation is supported by cohort evidence?
Different age and menopausal patterns can overlap and vary by compartment and site.
Every skeleton maintains identical bone mass until age 65.
Cortical and trabecular loss always occur in mutually exclusive age bands.
Any observed postmenopausal change is necessarily caused only by menopause.
Sections you finish are checked off in the contents.